EncepHeal engages academic institutions, private companies, foundations, and publicly funded government agencies to create a pipeline for therapeutics that lead to FDA approvals.
EncepHeal’s technology is an in-licensed chemical library of potent and selective modafinil analogues. These compounds offer a range of competitive pharmacokinetic advantages over the parent drug modafinil and other drugs currently being evaluated as treatments for psychostimulant use disorders.
Chief Executive Officer
Chief Scientific Officer
Steven R. Childers
Chief Research Officer